Management Comment "50% of patients (127 out of 255 enrolled patients) have completed the 96-week treatment period in the ongoing Phase 2b clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS). The trial’s external Data Safety Monitoring Board will review the results of an interim efficacy analysis in the fourth quarter of 2016. The purpose of the analysis will be to make recommendations to the National Institute of Neurological Diseases and Stroke (NINDS) regarding the trial.  "

"We look forward to providing further updates as we receive results of the interim analysis."